One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your ...
There's more to young biopharma companies than their numbers, but those numbers are still an important part of each ...
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene editing technologies enable precise modification of DNA, transforming ...
CRISPR Therapeutics focuses on developing gene-based medicines using its proprietary CRISPR/Cas9 platform. The company develops gene-based medicines, a transformative part of healthcare stocks. It ...
Morning Overview on MSN
The first baby treated with a custom CRISPR therapy is thriving a year later
One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
The EU has relaxed its rules on gene-editing. Now, only some gene-edited crops are regulated by the stringent GMO directive.
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...
10d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene editing technologies enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results